Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458028 · ClinicalTrials.gov registry record · Phase 1
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01458028 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 48 participants.
The verdict
NCT01458028, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Single dose study of BAY85-3934 compared to placebo in young/elderly male and female healthy subjects. The main focus of the study is to determine if the pharmacokinetics (drug levels in blood) of BAY85-3934 is similar or not in the four subject groups. Qualifying subjects will be dosed with a single tablet of BAY85-3934 (or placebo) and blood will be drawn over 4 days. The safety and tolerability of BAY85-3934 compared to placebo will also be evaluated over the 5 days of the study.
Interventions
- DRUG Placebo
- DRUG BAY85-3934
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458028
The ClinicalTrials.gov registry entry for NCT01458028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01458028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01458028 about?
NCT01458028 is a clinical study titled "Age and Gender Effects on the Pharmacokinetics of BAY85-3934". Single dose study of BAY85-3934 compared to placebo in young/elderly male and female healthy subjects. The main focus of the study is to determine if the pharmacokinetics (drug levels in blood) of BAY85-3934 is similar or not in the four subject groups. Qualifying subjects will be dosed with a singl...
What is the current status of trial NCT01458028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01458028?
The interventions under investigation include: Placebo (DRUG), BAY85-3934 (DRUG).
Who is sponsoring clinical trial NCT01458028?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.